Biochemical-markers for the diagnosis of bone metastasis: A clinical review

Cancer Epidemiology

Volumn 36, Issue 1, 2012, Pages 94-98

  Huang, Qian ^a   Ouyang, Xuenong ^b  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Fuzhou Genenal Hospital   (China)

Author keywords

Biochemical markers; Bone metastasis; Malignant tumor

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; OSTEOPONTIN; OSTEOPROTEGERIN; PYRIDINOLINE; TARTARIC ACID DERIVATIVE; TARTRATE RESISTANT ACID PHOSPHATASE ISOFORM; TUMOR MARKER; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO TERMINAL SEQUENCE; BIOLOGY; BONE METABOLISM; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CARBOXY TERMINAL SEQUENCE; HUMAN; LUNG CANCER; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY;

BONE NEOPLASMS; HUMANS; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855842037     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.02.001     Document Type: Review

References (65)

1. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
2. Coleman R., Brown J., Terpos E., Lipton A., Smith M.R., Cook R., et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008, 34:629-639.
3. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602.
4. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
5. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
6. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
7. Hamaoka T., Madewell J.E., Podoloff D.A., Hortobagyi G.N., Ueno N.T. Bone imaging in metastatic breast cancer. J Clin Oncol 2004, 22:2942-2953.
8. Daldrup-Link H.E., Franzius C., Link T.M., Laukamp D., Sciuk J., Jürgens H., et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001, 177:229-236.
9. Rybak L.D., Rosenthal D.I. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 2001, 45:53-64.
10. Fogelman I., Cook G., Israel O., Van der Wall H. Positron emission tomo-graphy and bone metastases. Semin Nucl Med 2005, 35:135-142.
11. Horak C.E., Steeg P.S. Metastasis gets site specific. Cancer Cell 2005, 8:93-95.
12. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
13. Kahn D., Weiner G.J., Ben-Haim S., Ponto L.L., Madsen M.T., Bushnell D.L., et al. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood 1994, 83:958-963.
14. van der Pluijm G., Sijmons B., Vloedgraven H., Deckers M., Papapoulos S., Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001, 16:1077-1091.
15. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., Klagsbrun M. Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986, 261:12665-12674.
16. Pfeilschifter J., Mundy G.R. Modulation of typeβtransforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987, 84:2024-2028.
17. Wymenga L.F., Boomsma J.H., Groenier K., Piers D.A., Mensink H.J. Routine bone scans in patients with prostate cancer related to serum prostate specific antigen and alkaline phosphatase. BJU Int 2001, 88:226-230.
18. Chung J.H., Park M.S., Kim Y.S., Chang J., Kim J.H., Kim S.K., et al. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 2005, 46:388-393.
19. Moss D.W. Alkaline phosphatase isoenzymes. Clin Chem 1982, 28:2007.
20. Smith M.R., Cook R.J., Coleman R., Brown J., Lipton A., Major P., et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007, 70:315-319.
21. Schindler F., Lajolo P.P. Bone and total alkaline phosphatase for screening skeletal metastasis in patients with solid tumours. Eur J Cancer Care (Engl) 2008, 17:152-156.
22. Hirsh V., Major P.P., Lipton A., Cook R.J., Langer C.J., Smith M.R., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236.
23. Hu X.Y., Zou Q.F., Jin C., Li W.D., Chen W.S., Ma L. Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non- small cell lung cancer and the bone metabolic markers. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:1343-1346.
24. Le Bricon T., Gay-Bellile C., Cottu P., Benlakehal M., Guillon H., Houzé P. Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer. J Clin Lab Anal 2010, 24:20-24.
25. Coleman R.E. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002, 94:2521-2523.
26. Jukkola A., Tahtela R., Tholix E., Vuorinen K., Blanco G., Risteli L., et al. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 1997, 57:5517-5520.
27. Koizumi M., Yonese J., Fukui I., Ogata E. The serum level of the aminoterminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001, 87:348-351.
28. Klepzig M., Jonas D., Oremek G.M. Procollagen type I amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res 2009, 29:671-673.
29. Zissimopoulos A., Stellos K., Matthaios D., Petrakis G., Parmenopoulou V., Babatsikou F., et al. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer, Comparison to CEA, CA15-3, PSA and bone scintigraphy. J BUON 2009, 14:463-472.
30. Zissimopoulos A., Bantis A., Stellos K., Petrakis G., Matthaios D. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. J BUON 2008, 13:69-74.
31. Koizumi M., Takahashi S., Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003, 23:4095-4099.
32. Henriksen K., Tanko L.B., Qvist P., Delmas P.D., Christiansen C., Karsdal M.A. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 2007, 18:681-685.
33. Ohashi T., Ichimura S. The mechanism of TRACP 5b maturation. Rinsho Byori 2007, 55:325-329.
34. Chao T.Y., Ho C.L., Lee S.H., Chen M.M., Janckila A., Yam L.T. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 2004, 11:511-516.
35. Wu Y.Y., Janckila A.J., Ku C.H., Yu C.P., Yu J.C., Lee S.H., et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity as a prognostic marker of survival in breast cancer with bone metastasis. BMC Cancer 2010, 10:158.
36. Salminen E., Ala-Houhala M., Korpela J., Varpula M., Tiitinen S.L., Halleen J.M., et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 2005, 44:742-747.
37. Tsai S.H., Chen C.Y., Ku C.H., Janckila A.J., Yam L.T., Yu J.C., et al. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis. Mayo Clin Proc 2007, 82:917-926.
38. Chao T.Y., Wu Y.Y., Janckila A.J. Tartrate-resistant acid phosphatase isoform 5b(TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chim Acta 2010, 411:1553-1564.
39. Zenger S., He W., Ek-Rylander B., Vassiliou D., Wedin R., Bauer H., et al. Differential expression of tartrate-resistant acid phosphatase isoform 5a and 5b by tumor and stromal cells in human metastatic bone disease. Clin Exp Metastasis 2011, 28:65-73.
40. Fisher L.W., Jain A., Tayback M., Fedarko N.S. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 2004, 10:8501-8511.
41. Bianco P., Fisher L.W., Young M.F., Termine J.D., Robey P.G. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int 1991, 49:421-426.
42. Papotti M., Kalebic T., Volante M., Chiusa L., Bacillo E., Cappia S., et al. Bone sialoprotein is predictive of bone metastasis in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 2007, 24:4818-4824.
43. Zhang L., Hou X., Lu S., Rao H., Hou J., Luo R., et al. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 2010, 67:114-119.
44. Waltregny D., Bellahcène A., Van Riet I., Fisher L.W., Young M., Fernandez P., et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998, 90:1000-1008.
45. Waltregny D., Bellahcène A., de Leval X., Florkin B., Weidle U., Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000, 15:834-843.
46. Bellahcene A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996, 11:665-670.
47. Ibrahim T., Leong I., Sanchez-Sweatman O., Khokha R., Sodek J., Tenenbaum H.C., et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000, 18:253-260.
48. Tu Q., Zhang J., Fix A., Brewer E., Li Y.P., Zhang Z.Y., et al. Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 2009, 218:135-145.
49. Fohr B., Dunstan C.R., Seibel M.J. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003, 88:5059-5075.
50. Leeming D.J., Koizumi M., Byrjalsen I., Li B., Qvist P., Tanko L.B. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15:32-38.
51. López-Carrizosa M.C., Samper-Ots P.M., Pérez A.R. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases. Clin Transl Oncol 2010, 12:568-573.
52. Kaira R., Murakami H., Kaira K., Takahashi T., Tsuya A., Nakamura Y., et al. N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 2010, 15:484-488.
53. Tamiya M, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, et al. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol; 22 January 2011 [Epub ahead of print].
54. Koopmans N., de Jong I.J., Breeuwsma A.J., van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007, 178:849-853.
55. Takahara K., Kamimura M., Hashidate H., Uchiyama S., Nakagawa H. Change of cross-linked telopeptide of type I collagen(ICTP) and other bone resorption markers in patients with bone fragility fractures. J Orthop Sci 2007, 12:219-226.
56. Kamiya N., Suzuki H., Yano M., Endo T., Takano M., Komaru A., et al. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 2010, 75:1446-1451.
57. Jung K, Miller K, Wirth M, Albrecht M, Lein M. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol; 22 December 2010 [Epub ahead of print].
58. Hayashi C., Rittling S., Hayata T., Amagasa T., Denhardt D., Ezura Y., et al. Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 2007, 101:979-986.
59. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Role of the metastasis-promoting osteopontin in the microenvironment. J Cell Mol Med 2010, 14:2037-2044.
60. Carlinfante G., Vassiliou D., Svensson O., Wendel M., Heinegård D., Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003, 20:437-444.
61. Chang Y.S., Kim H.J., Chang J., Ahn C.M., Kim S.K., Kim S.K. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007, 57:373-380.
62. Terpos E., Kiagia M., Karapanagiotou E.M., et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 2009, 29:1651-1657.
63. Ramankulov A., Lein M., Kristiansen G., Loening S.A., Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007, 67:330-340.
64. Mountzios G., Dimopoulos M.A., Bamias A., Papadopoulos G., Kastritis E., Syrigos K., et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappa B ligand(RANKL)/osteoprotegerin(OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007, 46:221-229.
65. Mountzios G., Terpos E., Syrigos K., Papadimitriou C., Papadopoulos G., Bamias A., et al. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl Res 2010, 155:247-255.